新一代可吸收多聚体药物涂层支架(DES)最新进展_Thomas课件.pptVIP

This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LIST MASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) * * * * * * * * * * * * * * * * * * * * * * * * Very Late Stent Thrombosis Signs of Safety Benefits Beyond One Year 0.0 0.5 1.0 1.5 2.0 2.5 3.0 0 3 6 9 12 15 18 21 24 Definite ST through 2 years % 2.0% 2.0% 2.2% 2.5% +0.2% Zoom at 1% scale +0.5% BES SES Primary and Secondary Definite ST BES N=857 SES$ N=850 Definite Stent Thrombosis % According to ARC Definition $Includes one secondary, definite ST occurring at 60 days in a patient who had early ST at 3 days *P values for superiority 4Klauss V., TCT 2009 BES SES P value* Aspirin - At 9 months - At 12 months 96.6% (n=818) 97.4% (n=798) 0.39 97.0% (n=810) 96.1% (n=801) 0.34 - At 24 months 94.9% (n=789) 94.2% (n=778) 0.58 Clopidrogel/Thienopyridine - At 9 months 95.6% (n=818) 95.2% (n=798) 0.81 - At 12 months 68.1% (n=810) 66.5% (n=801) 0.52 - At 24 months 23.4% (n=789) 24.3% (n=778) 0.72 Antiplatelet Agent Utilization4 *P values for superiority 4Klauss V., TCT 2009 Effect of DAPT Discontinuation4 % N=0/154 N=2/163 N=3/479 N=0/484 Overall Population Patient who d/c DAPT P = 0.73* *P values for superiority 4Klauss V., TCT 2009 Conclusions 2 years follow-up Non-inferiority